Europe Coronary Artery Bypass Graft Market Size, Share & Industry Trends Analysis Report By Procedure, By Method (Off-pump, On-pump, and Minimally Invasive Direct), By End-use (Hospitals, Cardiology Centers), By Country and Growth Forecast, 2023 - 2029
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Europe Coronary Artery Bypass Graft Market
Market Report Description
The Europe Coronary Artery Bypass Graft Market would witness market growth of 8.6% CAGR during the forecast period (2023-2029).
Technological advancements in cardiac surgery methods are anticipated to enhance the market's revenue growth. Recent advancements in surgical techniques and medical technology have increased CABG operations' effectiveness and minimal invasiveness. Robotic-assisted surgical tools, for instance, are employed increasingly commonly because they allow for more precise and minimally invasive treatments.
Increased demand for minimally invasive procedures drives the market's revenue growth. Because they need less downtime and have fewer incisions, less invasive CABG treatments are becoming more popular among patients. The market's anticipated revenue growth will be fueled by the growing popularity of hybrid treatments that combine CABG surgery with Percutaneous Coronary Intervention (PCI).
The number of deaths from cardiovascular disease exceeds 1.8 million in the European Union (EU) and 3.9 million in Europe per year. Additionally, CVD is responsible for 37% of all fatalities in the EU. Compared to Southern, Northern, and Western Europe, Central & Eastern Europe has higher mortality rates from ischemic heart disease (IHD) and stroke. Eighty-five million people are estimated to have CVD in Europe, with 49 million living in the EU. the European region's participants in the market have excellent growth potential.
The Germany market dominated the Europe Coronary Artery Bypass Graft Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,320.2 million by 2029. The UK market is exhibiting a CAGR of 7.6% during (2023 - 2029). Additionally, The France market would witness a CAGR of 9.4% during (2023 - 2029).
Based on Procedure, the market is segmented into Single CABG Surgery, Double CABG Surgery, Triple CABG Surgery, and Quadruple CABG Surgery. Based on Method, the market is segmented into Off-pump, On-pump, and Minimally Invasive Direct. Based on End-use, the market is segmented into Hospitals, Cardiology Centers, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Coronary Artery Bypass Graft Market is Projected to reach USD 20.6 Billion by 2029, at a CAGR of 9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Terumo Corporation, Karl Storz SE & Co. KG, Edwards Lifesciences Corporation, Johnson & Johnson (Ethicon, Inc.), Boston Scientific Corporation, Stryker Corporation, LivaNova PLC, Genesee BioMedical, Inc., and Vitalitec International Medizintechnik GmbH (Peters Surgical)
Scope of the Study
Market Segments Covered in the Report:
By Procedure
- Single CABG Surgery
- Double CABG Surgery
- Triple CABG Surgery
- Quadruple CABG Surgery
By Method
- Off-pump
- On-pump
- Minimally Invasive Direct
By End-use
- Hospitals
- Cardiology Centers
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Medtronic PLC
- Terumo Corporation
- Karl Storz SE & Co. KG
- Edwards Lifesciences Corporation
- Johnson & Johnson (Ethicon, Inc.)
- Boston Scientific Corporation
- Stryker Corporation
- LivaNova PLC
- Genesee BioMedical, Inc.
- Vitalitec International Medizintechnik GmbH (Peters Surgical)
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Related Reports: